Eli Lilly sells European rights to migraine medication for USD 50m
US-based Organon is continuously exploring opportunities to strengthen its women’s health portfolio, and two migraine drugs from Eli Lilly seem to fit in well with this focus.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Pfizer's migraine pill becomes part of a risk-sharing trial
For subscribers